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Abstract: The high prevalence of both obstructive sleep apnea (OSA) and chronic obstructive 
pulmonary disease (COPD) in Western societies is well documented. However, OSA frequently 
remains unrecognized and untreated among patients with COPD. Patients with both conditions 
have a greater risk for fatal and nonfatal cardiovascular events compared with patients with COPD 
or OSA alone. Efﬁ  cacious treatment with continuous positive airway pressure reduces the risk of 
cardiovascular complications in patients with OSA. The aim of the present review is to discuss 
the diagnostic approach to patients with both conditions and to delineate the beneﬁ  ts of timely 
recognition and treatment of OSA in patients with COPD.
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Introduction
The high prevalence of obstructive sleep apnea (OSA) among patients with chronic 
obstructive pulmonary disease (COPD) parallels the recent increase in obesity in 
Western societies. The prevalence of OSA among patients with COPD is similar to 
that of the general population (22% and 25%–29%, respectively) while the prevalence 
of obstructive airway disease among patients with OSA is even higher (29%–40%) 
(Young et al 1993; de Miguel et al 2002; Sanders et al 2003; O’Brien et al 2005). 
Although the clear common risk factors for such strong association are incompletely 
understood, the sheer number of patients with COPD and OSA accounts for their 
frequent coexistence.
Despite well documented high prevalence of both COPD and OSA, the coexistence 
of both conditions remains frequently unrecognized. Nocturnal arterial oxyhemoglobin 
desaturation and diurnal hypoxemia and hypercapnia are more pronounced in patients 
with coexistent COPD and OSA than in patients with either condition alone (Chaouat 
et al 1995; Sanders et al 2003). Patients with both conditions have a greater risk for 
pulmonary hypertension and right heart failure compared with patients with COPD 
or OSA alone (Bradley et al 1985; Chaouat et al 1995). Most importantly, patients 
with coexistent COPD and OSA have increased mortality compared with patients 
with OSA alone (Lavie et al 1995; Chaouat et al 1999). Treatment with continuous 
positive airway pressure (CPAP) reduces the risk of fatal and nonfatal cardiovascular 
events in patients with OSA (Marin et al 2005). Therefore, early recognition and 
prompt treatment of coexistent OSA in patients with COPD is essential for reducing 
morbidity and mortality in these patients.
The present review discusses the diagnostic challenges presented by the coexis-
tence of COPD and OSA, and emphasizes the importance of timely identiﬁ  cation and 
treatment of OSA in patients with COPD.International Journal of COPD 2008:3(2) 270
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Diagnostic challenges in patients 
with coexistent COPD and OSA
Patients with OSA experience repetitive episodes of hypoxia/
reoxygenation during apneas and hypopneas while asleep 
resulting in increased arterial stiffness, blood pressure, and 
sympathetic activity (Carlson et al 1993; Nieto et al 2000; 
Jelic et al 2002). Untreated OSA increases risk for hyper-
tension, heart failure, stroke, and increased mortality (He 
et al 1988; Peker et al 1999; Peppard et al 2000; Yaggi et al 
2005). Patients with untreated severe OSA have a higher 
incidence of fatal and nonfatal cardiovascular events than 
patients treated with CPAP after adjustment for pre-existing 
cardiovascular risk factors (Marin et al 2005).
COPD is an independent risk factor for increased cardio-
vascular mortality and morbidity. Forced expiratory volume 
in 1 second (FEV1) is as good a predictor of cardiovascular 
mortality as serum cholesterol (Hole et al 1996). Ischemic 
heart disease, and not respiratory failure, is the leading cause 
of death in COPD patients (Pauwels et al 2001). While right 
heart failure is a well established complication of COPD, 
the high prevalence of left ventricular (LV) systolic dys-
function in patients with COPD remains unclear. Patients 
with COPD are not at increased risk for hypertension or LV 
hypertrophy; however, they consistently show evidence of 
low-grade systemic inﬂ  ammation that plays a major role in 
the pathogenesis of atherosclerosis (Sin et al 2004). Patients 
with severe COPD and unknown OSA status are 2.18 and 
2.74 times more likely to have elevated and highly elevated, 
respectively, circulating C-reactive protein levels than control 
subjects (Sin et al 2003). Untreated OSA is associated with 
systemic inﬂ  ammation as well (Shamsuzzaman et al 2002). 
The presence of unrecognized OSA may potentiate sys-
temic inﬂ  ammation and accelerate progression of coronary 
atherosclerosis leading to increased cardiovascular morbidity 
and mortality in COPD patients.
Furthermore, untreated OSA causes excessive daytime 
sleepiness that leads to increased risk of accidents at work 
and while operating a motor vehicle (Sassani et al 2004). 
Utilization of healthcare resources and economic cost are 
23% to 50% greater among untreated OSA patients com-
pared with the age-matched subjects (Bahammam et al 1999; 
Smith et al 2002). Efﬁ  cacious treatment of OSA reduces the 
cardiovascular morbidity and mortality as well as cost of care 
(Marin et al 2005). Despite its signiﬁ  cant negative impact 
on public health, OSA remains frequently unrecognized and 
untreated.
Identifying patients who experience OSA-related arterial 
oxyhemoglobin desaturation is especially important in COPD 
patients since more pronounced nocturnal desaturation 
correlates with the development of pulmonary hypertension 
and adverse outcomes (McNicholas et al 1984; Bradley et al 
1985). The prevalence of OSA among patients with mild 
COPD equals that among general middle-age population 
(22% vs 29%) (Sanders et al 2003). An additional quarter 
of COPD patients with mild daytime hypoxemia suffer from 
nocturnal oxyhemoglobin desaturation even in the absence of 
OSA (Fletcher et al 1987). Progressive decline in FEV1 and 
forced vital capacity (FVC) ratio to below 65% is associated 
with accelerated increase in risk of oxyhemoglobin desatura-
tion during sleep (Sanders et al 2003). Taken together, these 
epidemiological data suggest that nocturnal oxyhemoglobin 
desaturation either related or unrelated to OSA is present in 
at least a half of COPD patients without signiﬁ  cant daytime 
hypoxemia.
Current guidelines for evaluation of nocturnal oxyhe-
moglobin saturation in COPD patients without signiﬁ  cant 
daytime hypoxemia are somewhat restrictive. Measuring 
nocturnal oxyhemoglobin saturation in COPD patients who 
have daytime arterial partial pressure of oxygen (PaO2) of 
55–59 mm Hg is not recommended, except in patients with 
unexplained polycythemia or cor pulmonale (Celli et al 
2004). Nocturnal polysomnography is recommended in 
COPD patients whose symptoms suggest coexistent OSA. 
This includes COPD patients who have daytime hypercapnia 
with only moderately reduced FEV1, those who are obese 
snorers, or those who develop headache after nocturnal 
oxygen therapy (Flenley 1985; Celli et al 2004). Witnessed 
apneas while asleep and daytime sleepiness are highly sug-
gestive of OSA (Hiestand et al 2006). However, the presence 
of concomitant OSA is often difﬁ  cult to predict from daytime 
symptoms in patients with COPD. A majority of patients with 
OSA do not have daytime hypercapnia or headache and some 
of them are not obese and have no daytime sleepiness (Young 
et al 1993; Resta et al 2000; Netzer et al 2003; Bradley 
et al 2007). Pulmonary function testing correlates poorly 
with nocturnal hypoxemia while moderate oxyhemoglobin 
desaturation during exercise has a weak predictive value for 
reduced nocturnal mean and nadir oxyhemoglobin saturation 
(Mulloy et al 1996). Signiﬁ  cant cardiovascular morbidity and 
mortality associated with untreated OSA that is reversible 
with CPAP treatment strongly support a more aggressive 
approach to diagnosis of coexistent OSA among patients 
with COPD (Marin et al 2005; Bradley et al 2007).
While the paucity of data regarding prevalence of 
unrecognized OSA in patients with COPD presents a major 
challenge, the prevalence of unrecognized COPD among International Journal of COPD 2008:3(2) 271
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patients with known OSA has seldom been addressed. 
Daytime hypercapnia, pulmonary hypertension, and noc-
turnal tachyarrhythmias may suggest the presence of unrec-
ognized COPD in patients with OSA (Fletcher et al 1987; 
Chaouat et al 1995; Resta et al 2002; Olmetti et al 2007). 
Among 265 patients with OSAS, the prevalence of daytime 
hypercapnia was 27% in the 30 patients with an associated 
COPD and 8% in the 235 patients without COPD (Chaouat 
et al 1995). Similarly, daytime hypercapnia was observed 
in 11% of 1141 OSA patients who were free of COPD and 
was related to the severity of obesity (Laaban et al 2005). 
Pulmonary hypertension is observed in 75% of patients with 
coexistent OSA and COPD (Fletcher et al 1987) and in only 
12%–20% of unselected OSA patients (Bradley et al 1985; 
Krieger et al 1989). Patients with coexistent OSA and COPD 
are 2.53 times more likely to experience tachyarrhythmias 
during sleep that patients with OSA alone (Olmetti et al 
2007). Patients with OSA who do not carry the diagnosis 
of COPD but experience daytime hypercapnia, pulmonary 
hypertension, and/or nocturnal tachyarrhythmias should be 
screened for the presence of coexistent COPD including the 
pulmonary function testing.
Considering that approximately half of patients with 
COPD who have nocturnal hypoxemia have coexistent OSA, 
clinicians should be vigilant in establishing the diagnosis of 
OSA in these patients. Readily available and inexpensive 
nocturnal oxymetry should be performed in COPD patients 
with mild daytime hypoxemia and/or FEV1/FVC ratio below 
65%. Patients with COPD who are diagnosed with nocturnal 
hypoxemia by nocturnal oxymetry should undergo attended 
nocturnal polysomnography to exclude coexistent OSA 
as a treatable cause of nocturnal hypoxemia (Figure 1). 
Timely diagnosis and treatment of coexistent OSA may 
reduce cardiovascular morbidity and mortality in patients 
with COPD.
Treatment of coexistent OSA 
and COPD
Effects of CPAP on lung function 
in coexistent OSA and COPD
Prospective studies of long-term CPAP therapy reported 
reduction in airway obstruction and improvement in gas 
exchange and respiratory muscle strength in patients with 
COPD and OSA (Mezzanotte et al 1994; Mansﬁ  eld et al 
1999; de Miguel et al 2002). CPAP therapy for 6 months 
reduces daytime arterial PaCO2 and increases daytime PaO2 
and FVC and FEV1 in these patients (de Miguel et al 2002). 
Improvement in spirometry and gas exchange persisted 
after 18 months of CPAP therapy (de Miguel et al 2002). 
In contrast, one retrospective study reported decrease in 
FVC and FEV1 after initiation of long-term CPAP therapy 
in patients with coexistent COPD and OSA (O’Brien et al 
2005). However, study sample was small (n = 35) and less 
than a third of enrolled patients were included in the ﬁ  nal 
analysis. The reasons for incomplete sample analysis and the 
precise timing of baseline and follow-up pulmonary function 
testing were not speciﬁ  ed making the results of this study 
difﬁ  cult to interpret.
The addition of long-term CPAP therapy to standard treat-
ment of COPD patients improves gas exchange, and airﬂ  ow 
obstruction while reducing hospitalization rates in patients 
with COPD and OSA (Mansﬁ  eld et al 1999; Pauwels et al 
2001; GOLD 2005). An improvement in gas exchange with 
CPAP has important implications when considering long-
term oxygen therapy in patients with coexistent COPD and 
OSA. Among 55 middle-aged men with daytime hypoxemia 
and coexistent COPD and OSA, only 22% continued to have 
daytime PaO2 60 mmHg after 6-month CPAP therapy (de 
Miguel et al 2002). Furthermore, CPAP therapy reduces 
elevated pulmonary and systemic arterial pressure in OSA 
(Arias et al 2006; Campos-Rodriguez et al 2007). This 
emphasizes the importance of timely diagnosis and treat-
ment of coexistent COPD and OSA to prevent development 
of severe cardiovascular complications.
Possible mechanisms responsible for CPAP mediated 
improvement in lung function in patients with coexistent 
COPD and OSA includes counteraction of auto-positive 
end-expiratory pressure, decreasing respiratory muscle 
load, and respiratory work of breathing (Petrof et al 1990; 
Mezzanotte et al 1994). In addition, CPAP may have a mild 
bronchodilatory effect by ameliorating chronic irritation 
and hyperresponsiveness of the upper airway caused by 
snoring and repetitive closing and opening in OSA (Chan 
et al 1988). Reduction in chronic airway edema results in 
increased airway diameter after CPAP therapy (Chan et al 
1988; Mansﬁ  eld et al 1999).
Polysomnography identiﬁ  es previously unrecognized 
OSA-related severe nocturnal hypoxemia in COPD patients 
that requires combined treatment with CPAP and supple-
mental oxygen. The number of prescriptions for long-term 
oxygen therapy increased 4-fold among 70 COPD patients 
after nocturnal polysomnography uncovered previously 
unrecognized OSA-related nocturnal hypoxemia (O’Brien 
et al 2005). Patients with coexisting COPD and OSA who 
require long-term oxygen therapy have less severe COPD International Journal of COPD 2008:3(2) 272
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Figure 1 Diagnostic and therapeutic approach to coexistent chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). Patients with COPD who 
fulﬁ  ll the current guidelines criteria for suspected OSA should undergo nocturnal polysomnography without delay. Patients with COPD who do not fulﬁ  ll the current guidelines 
criteria for suspected OSA but have mild daytime hypoxemia and/or forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) ratio less than 65% should 
undergo nocturnal oxymetry. COPD patients with abnormal nocturnal oxymetry should undergo nocturnal polysomnography to establish the diagnosis of possible coexistent 
OSA. Patients with coexistent COPD and OSA should be treated with continuous positive airway pressure therapy (CPAP) to reduce their cardiovascular morbidity and 
mortality.International Journal of COPD 2008:3(2) 273
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than patients receiving oxygen therapy due to COPD alone 
(O’Brien et al 2005). Therefore, all patients with mild to 
moderate COPD and concomitant daytime hypoxemia should 
undergo nocturnal oxymetry and/or polysomnography to 
establish the diagnosis of possible coexistent OSA.
While CPAP therapy is effective in most OSA patients 
with or without coexistent COPD, bilevel positive airway 
pressure (PAP) may be useful when patients experience 
difﬁ  culty exhaling against a ﬁ  xed pressure or have persistent 
intermittent nocturnal hypoxemia during CPAP titration 
despite adequate airﬂ  ow (Kushida et al 2006). This is usually 
due to COPD-related hypoventilation and ventilation-
perfusion mismatch. Bilevel PAP delivers a lower expiratory 
PAP and higher inspiratory PAP thereby augmenting 
ventilation (Sanders et al 1990; Schafer et al 1998). Some 
patients with coexistent OSA and COPD experience persistent 
intermittent nocturnal hypoxemia during CPAP and bilevel 
PAP titration despite adequate airﬂ  ow (Sampol et al 1996). 
PAP can be increased to ameliorate possible residual upper 
airway resistance. If increased PAP is ineffective or poorly 
tolerated, supplemental oxygen can be added to PAP to 
eliminate persistent intermittent nocturnal hypoxemia (Kakkar 
et al 2007).
The current guidelines suggest the initial follow-up 
within 1 month after the start of PAP treatment and sub-
sequent yearly and as needed follow-up visits, as well as 
objective monitoring of CPAP compliance (ATS 1994; 
Kushida et al 2006). Close follow-up that includes patient 
education, adjustment of facial interface, and treatment of 
nasal conditions improves adherence with PAP therapy 
(Kushida et al 2006).
Long-term oxygen therapy for nocturnal 
arterial oxyhemoglobin desaturation 
in COPD in the absence of OSA
Patients with a resting daytime PaO2 55 mm Hg are candi-
dates for continuous home oxygen therapy (Celli et al 2004). 
COPD patients with mild daytime hypoxemia (PaO2 60 mm 
Hg) do not qualify for home supplemental oxygen; however, 
more than a quarter of these patients experience nocturnal 
arterial oxyhemoglobin desaturation without evidence of 
OSA (Fletcher et al 1987). Nocturnal arterial oxyhemoglobin 
desaturation occurs mostly during REM sleep (Fletcher et al 
1987). Transient oxyhemoglobin desaturation in COPD prob-
ably results from a combination of alveolar hypoventilation 
and gas exchange abnormalities augmented by REM sleep-
related muscular atonia and changes in respiratory control 
(Weitzenblum et al 1997). Possible contribution of airﬂ  ow 
limitation has been suggested by a modest improvement 
in oxyhemoglobin desaturation during REM sleep after 
tiotropium use for 4 weeks in COPD patients without OSA 
(McNicholas et al 2004). Repetitive alveolar hypoxia and 
hypoxic vasoconstriction may lead to sustained pulmonary 
hypertension (Sajkov et al 1999; Fagan 2001). These patients 
have a greater mortality compared with COPD patients who 
do not experience nocturnal arterial oxyhemoglobin desatura-
tion (Fletcher et al 1992). Nasal oxygen therapy for 3 years 
signiﬁ  cantly reduced pulmonary artery pressure in COPD 
patients with nocturnal desaturation (Fletcher et al 1992).
The effect of long-term oxygen therapy on mortality in 
COPD patients with isolated nocturnal oxyhemoglobin desat-
uration remains unclear. One study reported a trend toward 
increased survival among COPD patients with nonapneic 
nocturnal desaturation who were treated with long-term oxy-
gen therapy (Fletcher et al 1992). Others reported no overall 
survival beneﬁ  t with nasal oxygen therapy in these patients 
(Gorecka et al 1997; Chaouat et al 1999). Low mortality 
rate in a small study sample precluded deﬁ  nitive conclusion 
about the effect of nocturnal nasal oxygen therapy on survival 
in COPD patients with nocturnal arterial oxyhemoglobin 
desaturation in one study (Chaouat et al 1999). COPD patients 
with nocturnal arterial oxyhemoglobin desaturation were not 
identiﬁ  ed in another cohort of COPD patients receiving long-
term oxygen therapy for mild daytime hypoxemia (Gorecka 
et al 1997). Pooling together COPD patients with and without 
nocturnal oxyhemoglobin desaturation may mask a beneﬁ  cial 
effect of long-term oxygen therapy on survival in COPD 
patients with nocturnal oxyhemoglobin desaturation.
In summary, patients with coexistent COPD and OSA 
have increased morbidity and mortality compared with 
patients with COPD or OSA alone. Treatment of OSA with 
CPAP reduces cardiovascular morbidity and mortality in 
patients with OSA. Clinicians should be vigilant in establish-
ing the diagnosis of OSA in patients with COPD who have 
nocturnal hypoxemia. Timely diagnosis and treatment of 
coexistent OSA may reduce cardiovascular morbidity and 
mortality in patients with COPD.
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